CIK 0000906709 · Non-accelerated filer<br>Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 943134940
- Phone
- 4154825300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $43,476
- in 2 filings
Net −$43,476. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-16 | Zalevsky Jonathan Chief R&D Officer | Sale | −7,662 | $13.83 | $106K | 212,803 |
| 2021-08-16 | Wilson Mark Andrew SVP & General Counsel | Sale | −1,910 | $13.83 | $26K | 72,900 |
| 2021-08-16 | ROBIN HOWARD W President & CEO | Sale | −11,515 | $13.83 | $159K | 424,123 |
| 2021-08-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Sale | −13,339 | $13.83 | $184K | 137,822 |
| 2021-08-16 | NORTHCOTT JOHN SVP & Chief Commercial Officer | Sale | −6,192 | $13.83 | $86K | 200,915 |
| 2021-08-16 | Labrucherie Gil M SVP, COO & CFO | Sale | −7,867 | $13.83 | $109K | 243,231 |
| 2021-07-22 | CHESS ROBERT Director | Option exercise | +91 | $13.80 | $1K | 280,664 |
| 2021-07-22 | CHESS ROBERT Director | Sale | −91 | $16.80 | $2K | 280,573 |
| 2021-07-22 | CHESS ROBERT Director | Option exercise · Stock Option | −91 | 18,279 | ||
| 2021-07-21 | CHESS ROBERT Director | Option exercise | +3,524 | $13.80 | $49K | 284,097 |
| 2021-07-21 | CHESS ROBERT Director | Sale | −3,524 | $16.81 | $59K | 280,573 |
| 2021-07-21 | CHESS ROBERT Director | Option exercise · Stock Option | −3,524 | 18,370 | ||
| 2021-07-20 | CHESS ROBERT Director | Option exercise | +2,106 | $13.80 | $29K | 282,679 |
| 2021-07-20 | CHESS ROBERT Director | Sale | −2,106 | $16.80 | $35K | 280,573 |
| 2021-07-20 | CHESS ROBERT Director | Option exercise · Stock Option | −2,106 | 21,894 | ||
| 2021-05-17 | Zalevsky Jonathan Chief R&D Officer | Sale | −31,111 | $18.30 | $569K | 235,065 |
| 2021-05-17 | Wilson Mark Andrew SVP & General Counsel | Sale | −1,917 | $18.30 | $35K | 74,810 |
| 2021-05-17 | Thomsen Jillian B. SVP & Chief Accounting Officer | Sale | −13,391 | $18.30 | $245K | 151,161 |
| 2021-05-17 | ROBIN HOWARD W President & CEO | Sale | −11,560 | $18.30 | $212K | 435,638 |
| 2021-05-17 | NORTHCOTT JOHN SVP & Chief Commercial Officer | Sale | −6,085 | $18.30 | $111K | 207,107 |
Page 13 of 18 · 355 trades